<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1251">
  <stage>Registered</stage>
  <submitdate>1/05/2006</submitdate>
  <approvaldate>17/05/2006</approvaldate>
  <actrnumber>ACTRN12606000182594</actrnumber>
  <trial_identification>
    <studytitle>Prospective study of predictors of the diagnosis of delirium or future development of the delirium: the association between serum anticholinergic levels and dignosis or future development of delirium in palliative care patients with advanced cancer.</studytitle>
    <scientifictitle>Prospective study of predictors of the diagnosis of delirium or future development of the delirium: the association between serum anticholinergic levels and dignosis or future development of delirium in palliative care patients with advanced cancer.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Delirium in advanced cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>patients with delirium in advanced cancer. Data collection will be daily from admission to death or discharge.</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Association of Serum Anticholinergic Levels (SAL) on admission to palliative care unit and at delirium occurrence with admission diagnosis of delirium or future occurrence during admission of delirium</outcome>
      <timepoint>Patients will be followed from admission to palliative care inpatient unit until death or discharge for delirium episdoes.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>i. Association of rating on Clinician rated Anticholinergic Scale  modified version (on admission and daily scores for period of observation) with occurrence of delirium.</outcome>
      <timepoint>on admission, daily</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ii.Sensitivity and specificity for SAL (taken on admission and level taken if delirium occurs i.e daily memorial delirium score of 10 or above on daily assessment) for diagnosis of incident and prevalent delirium.</outcome>
      <timepoint>on admission, at delirium</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>iii.Predictive model of investigational and clinical parameters on admission for incident and prevalent delirium.</outcome>
      <timepoint>on admission, at delirium</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>i.Admission to a palliative care inpatient unit.ii.male and female patients with Advanced cancer.iii.Predicted survival of greater than 7 days.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>i.Non-English speaking background.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Convenience sample</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/04/2006</anticipatedstartdate>
    <actualstartdate>2/05/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate>27/03/2009</actualenddate>
    <samplesize>200</samplesize>
    <actualsamplesize>126</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sacred Heart palliative care services and Flinders University</primarysponsorname>
    <primarysponsoraddress>Flinders University, Bedford Park, Adelaide South Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Flinders University</fundingname>
      <fundingaddress>Flinders University, Bedford Park, Adelaide South Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Hopehealthcare research fund</fundingname>
      <fundingaddress>Braeside Hospital, 340 Prairievale road Prairiewood 2164</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Sacred heart palliative care services research fund</fundingname>
      <fundingaddress>Darlinghurst Road, Darlinghurst</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Hope healthcare</sponsorname>
      <sponsoraddress>Braeside Hospital, 340 Prairievale road Prairiewood 2164</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Delirium is common in patients with advanced cancer, and presents with symptoms of disturbed sleep, attention, and/or memory; and restlessness or drowsiness. The cause of this is believed to be due to a disturbance of the cholinergic transmitter system in the brain. This could be due to anticholinergic activity of medication, or substances produced in acute illness. It is not possible to measure these abnormalities in the brain in the clinical setting, so a surrogate marker(s) that is routinely measured would be useful.  A serum anticholinergic assay can quantify anticholinergic activity in the blood. We aim to measure this on admission to a palliative care unit, and at an episode of delirium, and look at its levels in relation to its ability to predict the occurrence of delirium. We will also look for associations with other simple clinical and investigational measures, so a model can be developed to more accurately predict those at risk of delirium so preventive strategies and early identification can be utilised.</summary>
    <trialwebsite />
    <publication>Agar M, Draper B, Plummer J, Phillips P, and Currow D. Anticholinergic levels and risk of delirium in advanced cancer. Poster presentation. MASCC International symposium on supportive care in cancer. New York City, June 2012.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincents hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>13/03/2006</ethicapprovaldate>
      <hrec>H05/102</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Braeside Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>18/08/2005</ethicapprovaldate>
      <hrec>2005-08-1</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Meera Agar</name>
      <address>University of Technology Sydney, 235 Jones Street Ultimo 2007</address>
      <phone>+61 2 9514 4243</phone>
      <fax>+61 2 83829518</fax>
      <email>meera.agar@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Meera Agar</name>
      <address>PO Box 123 Ultimo NSW 2007
Office: Level 3, 235 Jones St, Ultimo NSW 2007 </address>
      <phone>+61 2 9514 4243</phone>
      <fax>o</fax>
      <email>meera.agar@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Meera Agar</name>
      <address>PO Box 123 Ultimo NSW 2007
Office: Level 3, 235 Jones St, Ultimo NSW 2007 </address>
      <phone>+61 2 9514 4243</phone>
      <fax />
      <email>meera.agar@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>